NCT01639248已完成2 期
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 3
- 主要终点
- Clinical benefit rate
研究概览
简要总结
The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily oral ENMD-2076.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically diagnosed locally advanced or metastatic triple-negative breast cancer defined as negative for estrogen receptor, progesterone receptor and HER
- •Patients must have measurable disease as defined by revised RECIST criteria (version 1.1, Appendix C) with one or more lesions that can be accurately measured in one or more dimensions within 4 weeks of entry. Areas of previous radiation may not serve as measurable disease.
- •Prior treatment with one to three lines of systemic chemotherapy for locally advanced or metastatic disease and two weeks from any previous anticancer therapy including biologics and recovered from expected toxicity; at least 4 weeks from major surgery and recovered; at least 3 weeks from radiation affecting more than 25% of bone marrow and recovered; and 2 weeks from other palliative radiation and recovered. No more than 450 mg/m2 cumulative dose of doxorubicin is allowed.
- •Because no dosing or adverse event data are currently available on the use of ENMD-2076 in patients <18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.
- •ECOG performance status ≤ 1 (Karnofsky ≥ 70%; see Appendix B).
- •Patients must have normal organ and marrow function
- •Patients must have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal within one month prior to start of study.
- •If the maximum number of non-biopsy subjects has accrued to the study, willingness to undergo 2 tumor biopsies. NOTE: Tumor biopsies may be required, depending on the number of subjects who have agreed to undergo correlative studies.
- •Ability to tolerate oral medications.
- •Women of child producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.
- •Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.
- •Availability of archival tumor tissue (core biopsy or surgical tumor blocks) for analysis. Sites will be asked to submit archival tissue (subjects may start the study if tissue is available at an outside hospital, but not yet requested or received).
排除标准
- •Women who are pregnant or nursing.
- •Have active, acute, or chronic clinically significant infections or bleeding.
- •Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); or history of congestive heart failure (equal to or greater than Grade 2).
- •Have active angina pectoris, stroke or recent myocardial infarction (within 6 months).
- •Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec.
- •Have additional uncontrolled serious medical or psychiatric illness.
- •Require therapeutic doses of any anti-coagulant.
- •CNS metastases.
- •Have any medical condition that would impair the administration of oral agents including recurrent bowel obstructions, inflammatory bowel disease or uncontrolled nausea, vomiting or diarrhea.
- •Have persistent 2+ protein by urinalysis (patients with 2+ proteinuria that have a spot protein:creatinine ratio of less than 0.3 may be enrolled) or a history of nephrotic syndrome.
- •Have an additional malignancy diagnosed within 5 years of study enrollment with the exception of basal or squamous cell skin cancer or cervical cancer in situ.
- •Patients may not be receiving any other investigational agents.
- •For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy.
研究组 & 干预措施
ENMD-2076 Treatment
Experimental
ENMD-2076
干预措施: ENMD-2076 (Drug)
结局指标
主要结局
Clinical benefit rate
时间窗: 24 weeks
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate CancerSmall Cell Prostate CancerNeuroendocrine Prostate CancerProstate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine MarkersNCT01799278Weill Medical College of Cornell University60
已完成
2 期
Study of Oral ENMD-2076 Administered to Patients With Ovarian CancerFallopian CancerPeritoneal CancerOvarian CancerNCT01104675CASI Pharmaceuticals, Inc.64
已完成
2 期
Treatment for Patients With Metastatic Thyroid CancerThyroid CancerNCT00176748University of Michigan Rogel Cancer Center3
Unknown
2 期
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover BiomarkersMetastatic Colorectal CancerNCT01949194Gerald Batist48
已完成
2 期
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast CancerTriple Negative Breast CancerNCT00951054Nippon Kayaku Co., Ltd.61